From prescription numbers to coverage hurdles, well cover the essential insights shaping the future of GLP-1s and their role in public health
Peptides that enhance metabolic resilience, preserve lean mass, improve behavioral regulation, or target comorbid conditions may find viable niches even if they do not match the magnitude of weight loss achieved with incretin therapies
Plus, more from The Bump: Uma Darji, MD, IBCLC, is a family physician and lactation consultant in Raleigh, North Carolina
[4] Liver enzymes (ALT, AST): While GLP-1medications are not known to cause liver injury and are generally safe in people without advanced liver disease, baseline liver tests may be obtained to evaluate overall metabolic health
Oral tablet: There is an oral GLP-1 marketed as Rybelsus, but its not FDA approved for weight loss